{
    "clinical_study": {
        "@rank": "55363", 
        "arm_group": [
            {
                "arm_group_label": "Normal Renal Function", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with CrCl \u2265 90 mL/min"
            }, 
            {
                "arm_group_label": "Subjects with End Stage Renal Disease", 
                "arm_group_type": "Experimental", 
                "description": "Subjects on hemodialysis"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to see how the body and the cancer react to an investigational\n      drug called carfilzomib, including measuring the amount of the study drug in the blood at\n      certain times following dosing. This study is being done in people with normal kidney\n      function and those with end-stage renal disease to see if they respond differently to the\n      study drug."
        }, 
        "brief_title": "Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Relapsed Multiple Myeloma", 
            "End-stage Renal Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Specifically, the purpose of this study is to assess the influence of End-stage Renal\n      Disease (ESRD) on area under the curve (both area under the curve, from time 0 to the last\n      concentration measured [AUC0-last] and area under the curve, from time 0 extrapolated to\n      infinity [AUC0-inf]) of carfilzomib 56 mg/m2 at Cycle 2 Day 1 (C2D1) in subjects with\n      relapsed multiple myeloma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Relapsed multiple myeloma\n\n          2. Evaluable disease (SPEP/UPEP/SFLC)\n\n          3. \u22651 and \u22643 prior lines of treatment\n\n          4. ESRD on hemodialysis or CrCl\u226590 mL/min\n\n          5. ECOG 0-2\n\n          6. Adequate organ and bone marrow function\n\n          7. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV),\n             symptomatic ischemia, conduction abnormalities uncontrolled by conventional\n             intervention or myocardial infarction within the protocol-specified period prior to\n             enrollment\n\n        Key Exclusion Criteria:\n\n          1. Immunogluobulin M (IgM) multiple myeloma\n\n          2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and\n             skin changes)\n\n          3. Waldenstr\u00f6m Macroglobulinemia\n\n          4. Active CHF (NYHA Class III-IV) ischemia, conduction abnormalities\n\n          5. Known HIV, recent HBV, HCV\n\n          6. Myelodysplastic Syndrome\n\n          7. Contraindication to test article, constituents, or required concomitant medications\n\n          8. Other investigational drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949532", 
            "org_study_id": "CFZ001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Normal Renal Function", 
                "Subjects with End Stage Renal Disease"
            ], 
            "description": "For Cycle 1, subjects will receive carfilzomib 20 mg/m2 IV on Days 1 and 2, followed by escalation to 27 mg/m2 on Days 8, 9, 15, and 16 of a 28-day cycle.  For Cycles 2 and higher, subjects will receive carfilzomib 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16, as tolerated.", 
            "intervention_name": "Carfilzomib", 
            "intervention_type": "Drug", 
            "other_name": "Kyprolis\u00ae (carfilzomib) for Injection"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Canton", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Gabrail Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Vanderbilt-Ingram Cancer Center, Henry-Joyce Cancer Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "UT Southwestern Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Baylor Charles A. Sammons Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "The Alfred Hospital, Malignant Haematology and Stem Cell Transplant Department"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia"
                    }, 
                    "name": "QEII Health Sciences Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "Sir Mortimer B. Davis-Jewish General Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease", 
        "other_outcome": [
            {
                "description": "Each evaluable subject's response (frequency and proportion) to treatment over the course of the study will be evaluated by the investigator according to the International Myeloma Working Group (IMWG) response criteria. Best overall response rate (ORR) is defined as partial response (PR) or better.", 
                "measure": "Exploratory Objectives: Best Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Each evaluable subject's response (frequency and proportion) to treatment over the course of the study will be evaluated by the investigator according to the International Myeloma Working Group (IMWG) response criteria. Clinical Benefit Response (CBR) is defined as ORR + minimal response (MR).", 
                "measure": "Exploratory Objectives: Clinical Benefit Response (CBR)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Duration of response will be defined as the time from first evidence of partial response (PR) or better to confirmation of progressive disease (PD).", 
                "measure": "Exploratory Objectives: Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Progression-free survival (PFS) will be defined as the time from the beginning of treatment to progressive disease (PD) or death.", 
                "measure": "Exploratory Objectives: Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "overall_contact": {
            "email": "medinfo@onyx.com", 
            "last_name": "Onyx Medical Information", 
            "phone": "1-877-669-9121"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoints are the time 0 to the last concentration measured [AUC0-last] and area under the curve, from time 0 extrapolated to infinity [AUC0-inf]of carfilzomib 56 mg/m2 at C2D1", 
            "measure": "Influence of End-stage Renal Disease on Area Under the Curve", 
            "safety_issue": "No", 
            "time_frame": "Cycle 2 Day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949532"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pharmacokinetics (PK) parameters comparison between subject cohorts of carfilzomib 56 mg/m2 at Cycle 2 Day 1 (C2D1), including maximum plasma concentration (Cmax), time to maximum concentration (tmax), clearance (CL), terminal half-life (t1/2), volume of distribution at steady state (Vss), and mean residence time (MRT)", 
                "measure": "Influence of End-stage Renal Disease on Additional Pharmacokinetics (PK) Parameters of Carfilzomib 56 mg/m2 at Cycle 2 Day 1 (C2D1)", 
                "safety_issue": "No", 
                "time_frame": "Cycle 2 Day 1"
            }, 
            {
                "description": "Pharmacokinetics (PK) parameters comparison between subject cohorts of carfilzomib 27 mg/m2 at Cycle 1 Day 16 (C1D16), including AUC0-last, AUC0-inf, Cmax, tmax, CL, t1/2, Vss, and MRT", 
                "measure": "Influence of End-stage Renal Disease on Additional Pharmacokinetics (PK) Parameters of Carfilzomib 27 mg/m2", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 16"
            }, 
            {
                "description": "Evaluation of pharmacokinetics (PK) parameters for major metabolites (metabolites PR-389/M14, PR-413/M15, and PR-519/M16) at Cycle 1 Day 16 (C1D16) (27 mg/m2) and Cycle 2 Day 1 (C2D1) (56 mg/m2) including AUC0-last, AUC0-inf, Cmax, tmax, t1/2, and MRT", 
                "measure": "Influence of End-stage Renal Disease on Additional Pharmacokinetics (PK) parameters for major metabolites", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 16 and Cycle 2 Day 1"
            }, 
            {
                "description": "Safety and tolerability of carfilzomib: Incidence, severity and causal relationship for all adverse events (AEs) (including serious adverse events [SAEs]); incidence of laboratory shifts for key analytes to and from limits of normal range; and Common Terminology Criteria for Adverse events (CTCAE) Grade relative to baseline in key laboratory parameters", 
                "measure": "Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Onyx Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Onyx Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}